Abstract
We provide the datasets used in this study. The datasets include: (1) incidence rates of hPIV associated ALRI (see "ALRI" file); (2) hospitalisation rates of hPIV associated ALRI (see "Hos" file); (3) hospitalisation rates of hPIV with hypoxemia (see "sHos" file); (4) in-hospital case fatality ratios of hPIV associated ALRI (see "CFR" file); (5) proportion positives of hPIV in hospitalised ALRI (see "prop" file); (6) the main results in this study (see "Main table results" file).
Background of this study:
Acute lower respiratory infections (ALRI) are one of the leading causes of morbidity and mortality in children globally, accounting for 10% of mortality in children under five years in 2017.1 Human parainfluenza virus (hPIV), including four major serotypes (hPIV-1 to hPIV-4), has been long considered a common virus in childhood ALRI. However, there are no global burden estimates of hPIV-associated ALRI among children under five years due to the limited data on incidence and mortality of hPIV-associated ALRI that have been readily available in published literature, especially by narrow age groups. Using the published and unpublished data on laboratory-confirmed (culture, immunofluorescence assay, or molecular test) hPIV burden, we sought to estimate the global and regional number of hPIV-associated ALRI cases, hospitalisations, and mortality by age strata among children under five years for 2018.
Two recent pooled analyses suggested that 43-87% of ALRI cases with laboratory-confirmed hPIV are attributable to hPIV in children under five years at population level (attributable fraction), with the attributable fraction varying by hPIV serotypes. To help better understand the contribution of hPIV in causing ALRI, we sought to estimate the global hPIV-attributable ALRI burden using type-specific data. These estimates should help guide health investment priorities and resource allocation. By raising awareness of the disease and healthcare burden they may also encourage and inform investment to accelerate the development of targeted prevention and treatment interventions. A few hPIV-3 candidate vaccines are under development, and have been assessed in phase I and II trials showing safety and immunogenicity in seronegative children above six months. A respiratory syncytial virus (RSV)/hPIV3 vaccine candidate has been assessed in a phase I trial, showing the possibility of using one vaccine to protect against both RSV and hPIV3 among young children. hPIV-1 and hPIV-2 candidate vaccines are also under development.
Background of this study:
Acute lower respiratory infections (ALRI) are one of the leading causes of morbidity and mortality in children globally, accounting for 10% of mortality in children under five years in 2017.1 Human parainfluenza virus (hPIV), including four major serotypes (hPIV-1 to hPIV-4), has been long considered a common virus in childhood ALRI. However, there are no global burden estimates of hPIV-associated ALRI among children under five years due to the limited data on incidence and mortality of hPIV-associated ALRI that have been readily available in published literature, especially by narrow age groups. Using the published and unpublished data on laboratory-confirmed (culture, immunofluorescence assay, or molecular test) hPIV burden, we sought to estimate the global and regional number of hPIV-associated ALRI cases, hospitalisations, and mortality by age strata among children under five years for 2018.
Two recent pooled analyses suggested that 43-87% of ALRI cases with laboratory-confirmed hPIV are attributable to hPIV in children under five years at population level (attributable fraction), with the attributable fraction varying by hPIV serotypes. To help better understand the contribution of hPIV in causing ALRI, we sought to estimate the global hPIV-attributable ALRI burden using type-specific data. These estimates should help guide health investment priorities and resource allocation. By raising awareness of the disease and healthcare burden they may also encourage and inform investment to accelerate the development of targeted prevention and treatment interventions. A few hPIV-3 candidate vaccines are under development, and have been assessed in phase I and II trials showing safety and immunogenicity in seronegative children above six months. A respiratory syncytial virus (RSV)/hPIV3 vaccine candidate has been assessed in a phase I trial, showing the possibility of using one vaccine to protect against both RSV and hPIV3 among young children. hPIV-1 and hPIV-2 candidate vaccines are also under development.
Data Citation
Wang, Xin; Nair, Harish. (2020). Global burden of acute lower respiratory infection associated with human parainfluenza virus in children under five years for 2018: a systematic review and meta-analysis, 1995-2019 [dataset]. University of Edinburgh, Usher Institute, Center for Global Health.
| Date made available | 1 Jul 2022 |
|---|---|
| Publisher | Edinburgh DataShare |
| Temporal coverage | 1 Jan 1995 - 31 Dec 2019 |
| Geographical coverage | Global |